Current management options for latent tuberculosis

A review

Brianna L. Norton, David P. Holland

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve comple- tion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens.

Original languageEnglish (US)
Pages (from-to)163-173
Number of pages11
JournalInfection and Drug Resistance
Volume5
Issue number1
StatePublished - 2012
Externally publishedYes

Fingerprint

Latent Tuberculosis
Isoniazid
Tuberculosis
Rifamycins
Standard of Care
Cause of Death
Economics
Costs and Cost Analysis
Incidence
Population
Therapeutics

Keywords

  • Interferon-gamma release assay
  • Isoniazid
  • Rifampin
  • Rifapentine
  • Tuberculin skin test

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology

Cite this

Current management options for latent tuberculosis : A review. / Norton, Brianna L.; Holland, David P.

In: Infection and Drug Resistance, Vol. 5, No. 1, 2012, p. 163-173.

Research output: Contribution to journalArticle

@article{3d8abdefceee4f83a96df470726157e5,
title = "Current management options for latent tuberculosis: A review",
abstract = "Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve comple- tion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens.",
keywords = "Interferon-gamma release assay, Isoniazid, Rifampin, Rifapentine, Tuberculin skin test",
author = "Norton, {Brianna L.} and Holland, {David P.}",
year = "2012",
language = "English (US)",
volume = "5",
pages = "163--173",
journal = "Infection and Drug Resistance",
issn = "1178-6973",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Current management options for latent tuberculosis

T2 - A review

AU - Norton, Brianna L.

AU - Holland, David P.

PY - 2012

Y1 - 2012

N2 - Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve comple- tion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens.

AB - Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve comple- tion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens.

KW - Interferon-gamma release assay

KW - Isoniazid

KW - Rifampin

KW - Rifapentine

KW - Tuberculin skin test

UR - http://www.scopus.com/inward/record.url?scp=84872897575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872897575&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 163

EP - 173

JO - Infection and Drug Resistance

JF - Infection and Drug Resistance

SN - 1178-6973

IS - 1

ER -